Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 5/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | CALCRL | Q16602 | 10/20 | 0.34 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ADM2 | Q7Z4H4 | 2/20 | 0.32 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.32 |
| ▸ | CALCR | P30988 | 1/20 | 0.32 |
| ▸ | CALCB | P10092 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1435883 | 0.87 | CALCA (0.41) | CALCACALCRLRAMP1NPC1ADM2 | |
| SCHEMBL16235885 | 0.77 | CALCA (0.46) | CALCACALCRLNPC1ADM2CALCB | |
| SCHEMBL6633546 | 0.77 | BACE1 (0.60) | BACE1 | |
| Hydrochloric Acid SCHEMBL6637596 | 0.75 | BACE1 (0.59) | BACE1 | |
| Hydrochloric Acid SCHEMBL6641315 | 0.75 | BACE1 (0.59) | BACE1 | |
| SCHEMBL550356 | 0.75 | CALCA (0.50) | CALCABACE1CALCRLNPC1 | |
| SCHEMBL15999444 | 0.74 | CALCA (0.44) | CALCACALCRLRAMP1NPC1 | |
| SCHEMBL31456516 | 0.74 | CALCA (0.44) | CALCACALCRLRAMP1NPC1 | |
| SCHEMBL15699749 | 0.74 | CALCA (0.44) | CALCACALCRLRAMP1NPC1 | |
| SCHEMBL30087869 | 0.74 | CALCA (0.44) | CALCACALCRLRAMP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087800-A1 | Spirooxindole derivatives are analgesics for the treatment of chronic pain. | ASTRAZENECA AB | 2004-05-06 | — | — | US | claimed |
| EP-1202994-B1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2004-04-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087800-A1 | Spirooxindole derivatives are analgesics for the treatment of chronic pain. | OPRK1, OPRD1, OPRL1 | CALCA 506/4885BACE1 4822/4885CALCRL 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.